Animal Cell Technology, National Research Council of Canada, 6100 Royalmount Avenue, Montréal, Québec, Canada.
Vaccine. 2010 May 7;28(21):3661-71. doi: 10.1016/j.vaccine.2010.03.029. Epub 2010 Mar 26.
Cell culture processes offer an attractive alternative to conventional chicken egg-based influenza vaccine production methods. However, most protocols still rely on the use of adherent cells, which makes process scale-up a challenging issue. In this study, it is demonstrated that the HEK-293 human cell line is able to efficiently replicate influenza virus. Production in serum-free suspension of HEK-293 cultures resulted in high titers of infectious influenza viruses for different subtypes and variants including A/H1, A/H3 and B strains. After virus adaptation and optimization of infection conditions, production in 3-L bioreactor resulted in titers of up to 10(9)IVP/mL demonstrating the scale-up potential of the process.
细胞培养工艺为传统的基于鸡卵的流感疫苗生产方法提供了一种有吸引力的替代方案。然而,大多数方案仍然依赖于贴壁细胞的使用,这使得工艺放大成为一个具有挑战性的问题。在这项研究中,证明了 HEK-293 人细胞系能够有效地复制流感病毒。在无血清悬浮的 HEK-293 培养物中进行生产,可产生高滴度的不同亚型和变体的传染性流感病毒,包括 A/H1、A/H3 和 B 株。经过病毒适应和感染条件的优化,在 3-L 生物反应器中的生产可达到高达 10(9)IVP/mL 的滴度,证明了该工艺的放大潜力。